Ensysce Biosciences Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Public

  • Employees
  • 10

Employees

  • Stock Symbol
  • ENSC

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.36
  • (As of Friday Closing)

Ensysce Biosciences General Information

Description

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Contact Information

Website
www.ensysce.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 7946 Ivanhoe Avenue
  • Suite 201
  • La Jolla, CA 92037
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 7946 Ivanhoe Avenue
  • Suite 201
  • La Jolla, CA 92037
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ensysce Biosciences Stock Performance

As of 20-Nov-2026, Ensysce Biosciences’s stock price is $0.36. Its current market cap is $7M with 19.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.36 $0.36 $0.23 - $1.85 $7M 19.5M 500K -$7.70

Ensysce Biosciences Financials Summary

As of 30-Sep-2026, Ensysce Biosciences has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 7,281 1,728 6,527 1,897
Revenue 0 0 0 0
EBITDA (90,970) (10,151) (6,697) (10,272)
Net Income (91,008) (10,176) (7,987) (10,613)
Total Assets 30,953 7,452 5,597 2,708
Total Debt 155 307 302 855
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ensysce Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ensysce Biosciences‘s full profile, request access.

Request a free trial

Ensysce Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer
Drug Discovery
La Jolla, CA
10 As of 2025

Rahway, NJ
 

Blue Bell, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ensysce Biosciences Competitors (51)

One of Ensysce Biosciences’s 51 competitors is Merck & Co., a Corporation company based in Rahway, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Merck & Co. Corporation Rahway, NJ
Mitochon Pharmaceuticals Venture Capital-Backed Blue Bell, PA
Acura Pharmaceuticals Formerly VC-backed Palatine, IL
Indivior Corporate Backed or Acquired North Chesterfield, VA
Fresenius Kabi Corporation Bad Homburg, Germany
You’re viewing 5 of 51 competitors. Get the full list »

Ensysce Biosciences Patents

Ensysce Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024248178-A1 Methadone active agents and methods of use thereof Pending 27-Mar-2023
EP-4688733-A2 Methadone active agents and methods of use thereof Pending 27-Mar-2023
US-20260226000-A1 Methadone active agents and methods of use thereof Pending 27-Mar-2023
WO-2024206289-A2 Methadone active agents and methods of use thereof Inactive 27-Mar-2023
WO-2024206289-A3 Methadone active agents and methods of use thereof Inactive 27-Mar-2023 C07C271/20
To view Ensysce Biosciences’s complete patent history, request access »

Ensysce Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ensysce Biosciences Acquisitions (3)

Ensysce Biosciences’s most recent deal was a Merger/Acquisition with Cy Biopharma. The deal was made on 05-Aug-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cy Biopharma 05-Aug-2026 Merger/Acquisition Drug Discovery
Leisure Acquisition 01-Jul-2021 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
Signature Therapeutics 31-Dec-2015 Merger/Acquisition Drug Discovery
To view Ensysce Biosciences’s complete acquisitions history, request access »

Ensysce Biosciences ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Ensysce Biosciences’s complete esg history, request access »

Ensysce Biosciences Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Cy Biopharma Baar, Switzerland 2020
Covistat

Ensysce Biosciences FAQs

  • When was Ensysce Biosciences founded?

    Ensysce Biosciences was founded in 2003.

  • Where is Ensysce Biosciences headquartered?

    Ensysce Biosciences is headquartered in La Jolla, CA.

  • What is the size of Ensysce Biosciences?

    Ensysce Biosciences has 10 total employees.

  • What industry is Ensysce Biosciences in?

    Ensysce Biosciences’s primary industry is Drug Discovery.

  • Is Ensysce Biosciences a private or public company?

    Ensysce Biosciences is a Public company.

  • What is Ensysce Biosciences’s stock symbol?

    The ticker symbol for Ensysce Biosciences is ENSC.

  • What is the current stock price of Ensysce Biosciences?

    As of 20-Nov-2026 the stock price of Ensysce Biosciences is $0.36.

  • What is the current market cap of Ensysce Biosciences?

    The current market capitalization of Ensysce Biosciences is $7M.

  • Who are Ensysce Biosciences’s competitors?

    Merck & Co., Mitochon Pharmaceuticals, Acura Pharmaceuticals, Indivior, and Fresenius Kabi are some of the 51 competitors of Ensysce Biosciences.

  • What is Ensysce Biosciences’s annual earnings per share (EPS)?

    Ensysce Biosciences’s EPS for 12 months was -$7.70.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process